Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
NCT00133887Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2004
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in squamous cell carcinoma (SCC) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Incidence of new squamous cell carcinoma at 5 years. Started Apr 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT00133887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133887.